Related Experiment Video
Updated: Jun 3, 2026
12:52
Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
Published on: November 28, 2015
Galectin-1 and immunotherapy for brain cancer
Tina Verschuere1, Steven De Vleeschouwer, Florence Lefranc
1Laboratory of Experimental Immunology, Catholic University Leuven, Leuven, Belgium.
Expert Review of Neurotherapeutics
|April 8, 2011
Summary
High-grade glioma patients have a poor prognosis despite treatment. Galectin-1, a protein found in these tumors, promotes immune evasion, hindering effective immunotherapy like dendritic cell vaccination.
Area of Science:
- Neuro-oncology
- Immunology
- Cancer Biology
Background:
- High-grade glioma (HGG) presents a dismal prognosis despite multimodal treatments.
- Active specific immunotherapy, including dendritic cell vaccination, offers a promising avenue for anti-tumoral immune response generation.
- Therapeutic success in immunotherapy necessitates not only enhancing effector immune responses but also downregulating counteracting tolerogenic signals.
Purpose of the Study:
- To review the role of galectin-1 in high-grade glioma.
- To explore galectin-1's contribution to immune escape in the context of glioma.
- To assess the implications of galectin-1 for immunotherapeutic strategies.
Main Methods:
- Literature review and evidence summary.
- Analysis of galectin-1 expression in high-grade glioma.
- Evaluation of galectin-1's function in immune modulation.
Main Results:
- Galectin-1 is abundantly expressed in high-grade glioma.
- Galectin-1 acts as a key mediator of glioma-induced immune escape.
- Evidence suggests galectin-1 actively suppresses anti-tumoral immune responses.
Conclusions:
- Galectin-1 is a significant factor in the immune evasion mechanisms employed by high-grade gliomas.
- Targeting galectin-1 may be crucial for overcoming immune tolerance and enhancing the efficacy of immunotherapies for glioma.
- Understanding galectin-1's role is vital for developing novel therapeutic strategies against high-grade glioma.
More Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...